អ្វីគ្រប់យ៉ាងអំពី Mibolerone (ពិនិត្យមើលដំណក់)

  1 ។ WWL70 គឺជាអ្វី?
  2.What is WWL70 material?
  3.WWL70 Background
  4.How WWL70 works?
  5.WWL70 Usage information
  6.WWL70 Methods
  7. WWL70 Results
  8.What is the dosage of WWL70 ?
  9.WWL70 Abstract


WWL70 video


I.WWL70 basic Characters:

ឈ្មោះ: WWL70
CAS: 947669-91-2
រូបមន្តម៉ូលេគុល: C27H23N3O3
ទម្ងន់​ម៉ូលេគុល: 437.5
ចំណុចរលាយ:
ឧបករណ៍ផ្ទុកទិន្នន័យ: + 4 ° C
color: crystalline solid


1.What is WWL70?aasraw

WWL70 is an anti-inflammatory therapeutic agent capable of inhibiting PGE2 and PGE2-G production, primarily due to its reduction of COX-2 and microsomal PGES-1/2 expression and their PGE2 biosynthesis activity in microglia cells, as well as in the EAE mouse brain.

WWL70(CAS 947669-91-2) is a selective inhibitor of α/β-hydrolase domain-containing 6 (ABHD6), a serine hydrolase that acts as an alternative hydrolase of the endocannabinoid 2-arachidonoylglycerol (2-AG). It has an IC50 value of 55-70 nM and 90-95% inihibition of ABDH6. WWL70 hs been used in a variety of studies as an ABHD6 antagonist.

It was shown to rescue impaired function of mGluR5 signaling, resulting in pain inhibition in arthritic rats. WWL70 was also used to show that ABHD6 is involved in brown adipose function and white adipose browning, and is a potential therapeutic target for obesity and type 2 diabetes.


Raw WWL70 (947669-91-2) hplc≥98% | AASraw powder


2 ។ តើអ្វីទៅ WWL70 material?aasraw

Name: WWL70
CAS:  947669-91-2
Molecular Formula:  C27H23N3O3
Molecular Weight:  437.5
Melt Point:
Storage Temp: +4°C
Color: crystalline solid

Raw WWL70 suppliers(947669-91-2) HPLC≥98% | AASraw


3.WWL70 Backgroundaasraw

α/β-Hydrolase domain 6 (ABHD6) is one of the major enzymes for endocannabinoid 2-arachidonoylglycerol (2-AG) hydrolysis in microglia cells. Our recent studies have shown that a selective ABHD6 inhibitor WWL70 has anti-inflammatory and neuroprotective effects in animal models of traumatic brain injury and multiple sclerosis. However, the role of ABHD6 in the neuroinflammatory response and the mechanisms by which WWL70 suppresses inflammation has not yet been elucidated in reactive microglia.


4 ។ របៀប WWL70 works?aasraw

For example, The hydrolytic activity and the levels of 2-AG in BV2 cells were measured by radioactivity assay and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The expression of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) synthases in microglia treated with lipopolysaccharide (LPS) with/without WWL70 was determined by western blot and quantitative RT-PCR. The conversion of 2-AG to PGE2 or PGE2-glyceryl ester (PGE2-G) was assessed by enzyme-linked immunoassay (EIA) or LC-MS/MS. The involvement of ABHD6 in PGE2 production was assessed using pharmacological inhibitors and small interfering RNA (siRNA).

The effect of WWL70 on PGE2biosynthesis activity in the microsome fraction from BV2 cells and experimental autoimmune encephalopathy (EAE) mouse brain was also examined.
We found that WWL70 suppressed PGE2 production in LPS-activated microgliavia cannabinoid receptor-independent mechanisms, although intracellular levels of 2-AG were elevated by WWL70 treatment. This reduction was not attributable to WWL70inhibition of ABHD6, given the fact that downregulation of ABHD6 by siRNA or use of KT182, an alternative ABHD6 inhibitor failed to suppress PGE2 production.

WWL70 attenuated the expression of COX-2 and PGES-1/2 leading to the downregulation of the biosynthetic pathways of PGE2 and PGE2-G. Moreover, PGE2 production from arachidonic acid was reduced in the microsome fraction, indicating that WWL70also targets PGE2 biosynthetic enzymes, which are likely to contribute to the therapeutic mechanisms of WWL70 in the EAE mouse model.
WWL70 is an anti-inflammatory therapeutic agent capable of inhibiting PGE2 and PGE2-G production, primarily due to its reduction of COX-2 and microsomal PGES-1/2 expression and their PGE2 biosynthesis activity in microglia cells, as well as in the EAE mouse brain.

Levonorgestrel របៀបដែលវាធ្វើការ, ការប្រើប្រាស់, ផលប៉ះពាល់ AASraw


5.WWL70 Usageaasraw

WWL70 is supplied as a crystalline solid. A stock solution may be made by dissolving the WWL70 in an organic solvent purged with an inert gas. WWL70 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of WWL70 in these solvents is approximately 1 mg/ml. WWL70 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, WWL70 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. WWL70 has a solubility of approximately 0.2 mg/mlin a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.


6.WWL70 Methodsaasraw

The hydrolytic activity and the levels of 2-AG in BV2 cells were measured by radioactivity assay and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The expression of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) synthases in microglia treated with lipopolysaccharide (LPS) with/without WWL70 was determined by western blot and quantitative RT-PCR. The conversion of 2-AG to PGE2 or PGE2-glyceryl ester (PGE2-G) was assessed by enzyme-linked immunoassay (EIA) or LC-MS/MS. The involvement of ABHD6 in PGE2 production was assessed using pharmacological inhibitors and small interfering RNA (siRNA). The effect of WWL70 on PGE2 biosynthesis activity in the microsome fraction from BV2 cells and experimental autoimmune encephalopathy (EAE) mouse brain was also examined.


7.WWL70 Resultsaasraw

We found that WWL70 suppressed PGE2 production in LPS-activated microglia via cannabinoid receptor-independent mechanisms, although intracellular levels of 2-AG were elevated by WWL70 treatment. This reduction was not attributable to WWL70 inhibition of ABHD6, given the fact that downregulation of ABHD6 by siRNA or use of KT182, an alternative ABHD6 inhibitor failed to suppress PGE2 production. WWL70 attenuated the expression of COX-2 and PGES-1/2 leading to the downregulation of the biosynthetic pathways of PGE2 and PGE2-G. Moreover, PGE2 production from arachidonic acid was reduced in the microsome fraction, indicating that WWL70 also targets PGE2 biosynthetic enzymes, which are likely to contribute to the therapeutic mechanisms of WWL70 in the EAE mouse model.

របៀបប្រើគ្រឿងញៀន KML-29 (1380424-42-9) ធ្វើការជាអ្នកញៀន | AASraw


8 ។ តើអ្វីជា dosage of WWL70?aasraw

Solubility & Usage Info:
DMSO to 10 mM, clear (warmed)
ដំបូន្មានស្ថេរភាពនិងរលាយ:
Some solutions can be difficult to obtain and can be encouraged
by rapid stirring, sonication or gentle warming (in a 45-60°C
water bath).
Information concerning product stability, particularly in solution,
has rarely been reported and in most cases we can only offer a
general guide. Our standard recommendations are:
SOLIDS: Provided storage is as stated on the product label and
the vial is kept tightly sealed, the product can be stored for up to
6 months from date of receipt.
SOLUTIONS: We recommend that stock solutions, once
prepared, are stored aliquoted in tightly sealed vials at -20°C or
below and used within 1 month. Wherever possible solutions
គួរតែត្រូវបានធ្វើឡើងនិងត្រូវបានប្រើនៅថ្ងៃដដែល។


9.WWL70 Abstractaasraw

α/β-Hydrolase domain 6 (ABHD6) is one of the major enzymes for endocannabinoid 2-arachidonoylglycerol (2-AG) hydrolysis in microglia cells. Our recent studies have shown that a selective ABHD6 inhibitor WWL70 has anti-inflammatory and neuroprotective effects in animal models of traumatic brain injury and multiple sclerosis. However, the role of ABHD6 in the neuroinflammatory response and the mechanisms by which WWL70 suppresses inflammation has not yet been elucidated in reactive microglia.The hydrolytic activity and the levels of 2-AG in BV2 cells were measured by radioactivity assay and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS).

The expression of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) synthases in microglia treated with lipopolysaccharide (LPS) with/without WWL70 was determined by western blot and quantitative RT-PCR. The conversion of 2-AG to PGE2 or PGE2-glyceryl ester (PGE2-G) was assessed by enzyme-linked immunoassay (EIA) or LC-MS/MS. The involvement of ABHD6 in PGE2 production was assessed using pharmacological inhibitors and small interfering RNA (siRNA). The effect of WWL70 on PGE2 biosynthesis activity in the microsome fraction from BV2 cells and experimental autoimmune encephalopathy (EAE) mouse brain was also examined.We found that WWL70 suppressed PGE2 production in LPS-activated microglia via cannabinoid receptor-independent mechanisms, although intracellular levels of 2-AG were elevated by WWL70 treatment.

This reduction was not attributable to WWL70 inhibition of ABHD6, given the fact that downregulation of ABHD6 by siRNA or use of KT182, an alternative ABHD6 inhibitor failed to suppress PGE2 production. WWL70 attenuated the expression of COX-2 and PGES-1/2 leading to the downregulation of the biosynthetic pathways of PGE2 and PGE2-G. Moreover, PGE2 production from arachidonic acid was reduced in the microsome fraction, indicating that WWL70 also targets PGE2 biosynthetic enzymes, which are likely to contribute to the therapeutic mechanisms of WWL70 in the EAE mouse model.WWL70 is an anti-inflammatory therapeutic agent capable of inhibiting PGE2 and PGE2-G production, primarily due to its reduction of COX-2 and microsomal PGES-1/2 expression and their PGE2 biosynthesis activity in microglia cells, as well as in the EAE mouse brain.

Potential actions of WWL70 on PGE 2 and PGE 2 -G production in microglia. 2-AG is mainly metabolized to arachidonic acid, which in turn converts to PGE 2 by catalysis of COX-1/2 and mPGESs. WWL70 inhibits ABHD6 thereby increasing the levels of 2-AG and reduces the production of PGE 2 by inhibiting PGE 2 synthetic enzymes. 2-AG can also be oxygenated by COX-2 and then converted to PGE 2 glycerol ester by mPGESs, which is also inhibited by WWL70


0 ចុច Like
ចំនួនមើល 97

ទុកឱ្យសេចក្តីអធិប្បាយ

សូមបញ្ចូលឈ្មោះរបស់អ្នក។ សូមបញ្ចូលអាសយដ្ឋានអ៊ីម៉ែលត្រឹមត្រូវ។ សូមបញ្ចូលសារ។

Captcha *